Published in Transplantation on December 15, 1999
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol (2009) 1.04
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood (2009) 1.03
Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther (2009) 0.97
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci (2008) 0.93
Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. Immunology (2010) 0.89
Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol (2010) 0.85
New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci (2010) 0.84
Engineered CD3 antibodies for immunosuppression. Clin Exp Immunol (2003) 0.80
CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. Rev Diabet Stud (2012) 0.80
Future prospects for anti-cytokine treatment. Ann Rheum Dis (2000) 0.79
Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody. Clin Exp Immunol (2003) 0.78
Modulation of the human T cell response by a novel non-mitogenic anti-CD3 antibody. PLoS One (2014) 0.78
Non FcR-binding murine antihuman CD3 monoclonal antibody is capable of productive TCR signalling and induces proliferation in the presence of costimulation. Clin Exp Immunol (2001) 0.77
Characterization of a surrogate murine antibody to model anti-human CD3 therapies. MAbs (2013) 0.77
Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. J Clin Immunol (2015) 0.77
Immunotherapy in autoimmune type 1 diabetes. Rev Diabet Stud (2012) 0.76
Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance. Front Immunol (2015) 0.75
Bioengineered monoclonals--easier on patients, but still hard on rejection. Transplantation (1999) 0.75
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 8.59
Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1979) 6.10
"Infectious" transplantation tolerance. Science (1993) 4.98
Reshaping human antibodies for therapy. Nature (1988) 4.82
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cerebellum. J Physiol (1981) 4.05
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I. Science (1988) 3.03
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Rapamycin for immunosuppression in organ allografting. Lancet (1989) 2.51
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
The international spread of methicillin-resistant Staphylococcus aureus. J Hosp Infect (1987) 2.46
Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med (1999) 2.35
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
Experimental arthritis associated with auto-immunization to inflammatory exudates. Ann Rheum Dis (1966) 2.22
The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J Biol Chem (1995) 2.20
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med (1984) 2.10
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Immunofluorescent localization of three Na,K-ATPase isozymes in the rat central nervous system: both neurons and glia can express more than one Na,K-ATPase. J Neurosci (1991) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc (1979) 1.94
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
Fish consumption and cancer risk. Am J Clin Nutr (1999) 1.94
The native rat olfactory cyclic nucleotide-gated channel is composed of three distinct subunits. J Neurosci (1999) 1.93
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Changing pattern of organ donation at a single center: are potential brain dead donors being lost to donation after cardiac death? Am J Transplant (2010) 1.84
Deficit of suppressor T cells in active multiple sclerosis. Lancet (1980) 1.83
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet (2001) 1.81
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol (2013) 1.79
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol (1990) 1.79
Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis (1984) 1.78
The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 1.78
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 1.77
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant (1994) 1.76
Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci U S A (1997) 1.75
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 1.72
Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol (2001) 1.70
Selected food intake and risk of endometriosis. Hum Reprod (2004) 1.70
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
JCAH accreditation and the hospital library: a guide for librarians. Bull Med Libr Assoc (1980) 1.68
The role of exoenzyme S in infections with Pseudomonas aeruginosa. J Infect Dis (1985) 1.68
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Self-assembly and catalytic activity of the pyruvate dehydrogenase multienzyme complex of Escherichia coli. Nature (1977) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. I. A hybridoma secreting antibody against a marker specific for human B lymphocytes. Clin Exp Immunol (1980) 1.66
T cell-dependent mediator in the immune response. II. Physical and biological properties. Immunology (1974) 1.65
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol (2000) 1.60
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
Parasitic worms and inflammatory diseases. Parasite Immunol (2006) 1.58
Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol (2005) 1.57
Reproductive factors, family history, occupation and risk of urogenital prolapse. Eur J Obstet Gynecol Reprod Biol (1999) 1.57
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol (2000) 1.55
Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol (1998) 1.55
Kidney transplantation in the dog receiving FK-506. Transplant Proc (1987) 1.54
Induction of tolerance by monoclonal antibody therapy. Nature (1986) 1.53
Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant (2001) 1.52
Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells. Am J Transplant (2013) 1.52
Dietary factors and the risk of psoriasis. Results of an Italian case-control study. Br J Dermatol (1996) 1.51
Intensive plasmapheresis as a therapeutic measure in Rhesus-immunised women. Lancet (1970) 1.51
Cooperation across the histocompatibility barrier. Nature (1975) 1.51
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol (1999) 1.50
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. Immunology (1976) 1.49